Lixisenatide

Description: Lixisenatide is a short-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) with IC50 value of 1.4 nM for the human GLP-1 receptor in in vitro receptor binding studies. It can be administered through once-daily regimen. Lixisenatide is able to protect Ins-1 cells (a rat-derived beta-cell line) from both lipid- and cytokine-induced apoptosis. More importantly, Lixisenatide can also prevent lipotoxicity-induced insulin depletion in human islets and preserve insulin production, storage and pancreatic beta-cell function in vitro.

References: Regul Pept. 2010 Sep 24; 164(2-3):58-64; J Pharmacol Exp Ther. 2003 Nov; 307(2):490-6.